Monopar, Cancer Research UK partner for new oncology compound
HuATN-658 is designed to target the cell surface protein uPAR, which is found in high levels in some of the most deadly cancers. As part of the deal,
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).